Advertisement


Patrick Schöffski, MD, MPH, on RCC: Final Results of the EORTC 90101 CREATE Trial

2018 Genitourinary Cancers Symposium

Advertisement

Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification (Abstract 580).



Related Videos

Prostate Cancer
Immunotherapy

Fatima Karzai, MD, on Prostate Cancer: Treatment Study Results

Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected ...

Kidney Cancer

Daniel J. George, MD, on RCC: Study Results on Adjuvant Treatment

Daniel J. George, MD, of Duke University Medical Center, discusses phase III findings on adjuvant sunitinib in patients with high-risk renal cell carcinoma, in an exploratory pharm...

Bladder Cancer

Joaquim Bellmunt, MD, PhD, on Urothelial Cancer: Results From the KEYNOTE-045 Trial

Joaquim Bellmunt, MD, PhD, of the Dana-Farber Cancer Institute, discusses phase III 2-year follow-up findings on pembrolizumab vs investigator’s choice (paclitaxel, docetaxel, or v...

Bladder Cancer

John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial

John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radi...

Bladder Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Results From the CheckMate 032 Trial

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses longer-term efficacy and safety findings on nivolumab monotherapy in metastatic urothelial carcinoma...

Advertisement

Advertisement



;
Advertisement